Clinical trial
A Phase 2a, 24-Week, Multi-Center, Open-Label Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT03591926 is registered in ClinicalTrials.gov with Biosplice Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, 24-Week, Multi-Center, Open-Label Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Biosplice Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- January 31, 1900
- Completion date
- January 31, 1900
- Enrollment
- 0 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.